IVI and Netherlands

 

Member State Relations

 

On October 28, 1996, Permanent Representative of the Kingdom of the Netherlands. H.E. Nicolaas H. Biegman, signed the IVI Establishment Agreement.

 

On March 2, 1998, the States General of the Netherlands ratified the IVI Establishment Agreement.

 

In 1998, the Embassy of the Netherlands in Seoul, Korea donated $5,145 USD to IVI.

 

Dutch Leadership at IVI

 

Dr. Claire Boog represented the Netherlands on the IVI Board of Trustees from 2010 to 2013.

 

Professor Bernard Van der Zeijst represented the Netherlands on the IVI Board of Trustees from 2004 to 2010.

 

Ongoing Collaboration

 

Vaccines Against Schistosomiasis for Africa (VASA)

European Union Horizon 2020 Grant: 815643

 

With a €6.6 million Euro grant from EU Horizons 2020, The University of Cambridge and IVI launched VASA in 2019 to conduct a Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in Madagascar. This project includes disease surveillance and cost-effectiveness studies, the formation of a global consortium to advance schistosomiasis vaccine research. 

 

The Leiden University Medical Center in the Netherlands is a VASA consortium partner. In 2024, the project completed a seroepidemiology study, a controlled human infection model study, conducted in Netherlands, and a Phase Ib clinical trial at its Madagascar site to assess the safety and reactogenicity of the SchistoShield® vaccine. The outcome of the project will help inform vaccine development and guide control measures.

 

Previous Collaboration

 

In 2013, IVI and Intravacc signed a MoU outlining collaborative opportunities in vaccine technology R&D and vaccinology capacity building in developing countries.